Rivoceranib
- Generic Name
- Rivoceranib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Not Applicable
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma(HCC)
- Interventions
- Drug: FOLFOX4Procedure: HAICProcedure: Local treatmentDrug: The original treatment regimen
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanjing Tianyinshan Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06893887
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Phase 2
Not yet recruiting
- Conditions
- Gastric CancerHER2 + Gastric CancerPD-L1 PositiveCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 140
- Registration Number
- NCT06881017
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Phase 2
Recruiting
- Conditions
- Adrenal Cortical CarcinomaAdrenal Cortical CancerAdrenal Cancer
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06831175
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Small Cell Lung Cancer Extensive Stage
- Interventions
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06786312
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 43
- Registration Number
- NCT06759090
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Phase 2
Recruiting
- Conditions
- Unresectable Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06749730
- Locations
- 🇨🇳
HeNan, Zhengzhou, China
First-line Treatment of Advanced/unresectable DDLPS
Phase 2
Not yet recruiting
- Conditions
- Dedifferentiated LiposarcomaSoft Tissue Sarcoma (STS)
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 49
- Registration Number
- NCT06694324
- Locations
- 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
Phase 2
Not yet recruiting
- Conditions
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06693128
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳Changhai Hospital, Shanghai, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, China
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06546280
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Hepatocellular CarcinomaSBRTImmune Checkpoint BlockadeTyrosine Kinase Inhibitor
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06538935
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath